Keros Therapeutics (KROS) News Today $11.00 -0.03 (-0.23%) Closing price 03:59 PM EasternExtended Trading$11.03 +0.02 (+0.23%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Keros Therapeutics (KROS) to Release Quarterly Earnings on WednesdayKeros Therapeutics (NASDAQ:KROS) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 2:39 AM | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Short Interest UpdateKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 4,260,000 shares, an increase of 6.0% from the January 15th total of 4,020,000 shares. Based on an average trading volume of 1,500,000 shares, the days-to-cover ratio is currently 2.8 days.February 17, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for KROS FY2028 Earnings?February 12, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSFebruary 11, 2025 | prnewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Moderate Buy" by AnalystsFebruary 11, 2025 | americanbankingnews.comLeerink Partnrs Has Bullish Outlook for KROS FY2028 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2028 earnings per share estimates for shares of Keros Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the cFebruary 10, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy ratingFebruary 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSFebruary 4, 2025 | prnewswire.comSG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)SG Americas Securities LLC bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,493 shares of the company's stock, valued at approximately $388,February 4, 2025 | marketbeat.comKeros Therapeutics to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSJanuary 28, 2025 | prnewswire.comAssenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Assenagon Asset Management S.A. trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 71.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,937 shares of theJanuary 25, 2025 | marketbeat.comKeros Therapeutics (KROS) Gets a Buy from ScotiabankJanuary 24, 2025 | markets.businessinsider.comKEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. ...January 24, 2025 | gurufocus.comKEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the FirmJanuary 24, 2025 | globenewswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)January 22, 2025 | tmcnet.comCantor Fitzgerald Predicts KROS FY2025 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Keros Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will earnJanuary 22, 2025 | marketbeat.comCantor Fitzgerald Downgrades Keros Therapeutics (KROS)January 22, 2025 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROSJanuary 21, 2025 | prnewswire.comKeros Therapeutics downgraded to Neutral from Overweight at Cantor FitzgeraldJanuary 21, 2025 | markets.businessinsider.comKeros spikes as Teva deal takes effect; Cantor downgrades on trial setbackJanuary 21, 2025 | msn.comKeros stock climbs on Takeda deal effectivenessJanuary 21, 2025 | in.investing.comKeros Therapeutics stock rating cut to Neutral, cites dosing setbackJanuary 21, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to NeutralCantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday.January 21, 2025 | marketbeat.comWedbush Downgrades Keros Therapeutics (KROS)January 18, 2025 | msn.comKeros Therapeutics Downgraded to ‘Hold’ Amid Strategic Shifts and Program RemovalJanuary 17, 2025 | markets.businessinsider.comKeros Therapeutics price target lowered to $15 from $40 at Piper SandlerJanuary 17, 2025 | markets.businessinsider.comPiper Sandler cuts Keros stock target to $15, keeps OverweightJanuary 17, 2025 | msn.comKeros Therapeutics (KROS) Gets a Buy from Piper SandlerJanuary 17, 2025 | markets.businessinsider.comPiper Sandler Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00Piper Sandler dropped their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday.January 17, 2025 | marketbeat.comKeros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by WedbushWedbush downgraded shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and set a $15.00 price objective for the company. in a research note on Friday.January 17, 2025 | marketbeat.comGuggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS)Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research report on Friday.January 17, 2025 | marketbeat.comScotiabank Remains a Buy on Keros Therapeutics (KROS)January 17, 2025 | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Buy from OppenheimerJanuary 17, 2025 | markets.businessinsider.comScotiabank Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock PriceScotiabank dropped their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research report on Thursday.January 16, 2025 | marketbeat.comOppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research note on Thursday.January 16, 2025 | marketbeat.comKeros stock price target cut on study terminationJanuary 16, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Sets New 52-Week Low - What's Next?Keros Therapeutics (NASDAQ:KROS) Sets New 52-Week Low - Here's What HappenedJanuary 16, 2025 | marketbeat.comKeros Therapeutics: Buy Rating Affirmed Despite Setbacks, Driven by Strong Pipeline and Strategic PartnershipsJanuary 16, 2025 | markets.businessinsider.comKeros Therapeutics price target lowered to $32 from $33 at BofAJanuary 16, 2025 | markets.businessinsider.comKeros Therapeutics Halts Pulmonary Hypertension Treatment Trials Due to Adverse EffectsJanuary 15, 2025 | marketwatch.comKeros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment TrialsJanuary 15, 2025 | marketwatch.comKeros Therapeutics stock falls after trial haltJanuary 15, 2025 | in.investing.comKeros Therapeutics Halts All Dosing In Phase 2 TROPOS Trial For PAH Due To Safety ConcernsJanuary 15, 2025 | markets.businessinsider.comKeros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz SpikesJanuary 15, 2025 | msn.comKeros Therapeutics (NASDAQ:KROS) Shares Down 8.9% - What's Next?Keros Therapeutics (NASDAQ:KROS) Trading Down 8.9% - Here's WhyJanuary 15, 2025 | marketbeat.comKeros halts hypertension treatment trial on safety issuesJanuary 15, 2025 | reuters.comKeros Therapeutics Announces Additional Update on the Phase 2 TROPOS TrialJanuary 15, 2025 | globenewswire.comKeros Therapeutics (NASDAQ:KROS) Trading Down 8.9% - Here's What HappenedKeros Therapeutics (NASDAQ:KROS) Shares Down 8.9% - Here's What HappenedJanuary 13, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by BrokeragesKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and ten have given a buy recommendaJanuary 12, 2025 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼0.650.60▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼24▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Wave Life Sciences News Apogee Therapeutics News Evotec News Disc Medicine News Arcutis Biotherapeutics News Amphastar Pharmaceuticals News Immunocore News Kiniksa Pharmaceuticals News Dyne Therapeutics News Structure Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
